Ares Financial Consulting
EWTX icon

Ares Financial Consulting’s Edgewise Therapeutics EWTX Stock Holding History

Ares Financial Consulting’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-23
Closed -$934 – 1094
2026
Q2 		$934 Buy
+23
New +$793 ﹤0.01% 1016

Other funds holding EWTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

Ares Financial Consulting's EWTX Position: Q3 2026 in Review

Ares Financial Consulting sold out of Edgewise Therapeutics (EWTX) in Q3 2026, closing a stake of 23 shares — an estimated $934 sold.

Ares Financial Consulting first reported a position in EWTX in Q2 2026 and held it in 1 quarter. The position peaked at $934 in Q2 2026. 153 funds tracked by Wall St. Rank hold EWTX as of Q3 2026.

  • Ares Financial Consulting reported no remaining Edgewise Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Ares Financial Consulting sold 23 Edgewise Therapeutics shares in Q3 2026, an estimated $934.
  • Ares Financial Consulting first reported a position in Edgewise Therapeutics in Q2 2026 and held it in 1 quarter.
  • Ares Financial Consulting's Edgewise Therapeutics position peaked at $934 in Q2 2026.
  • 153 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.